NaturalFNP Signs 5 Billion KRW Beta-Glucan Supply Contract with Betagen Networks

[Asia Economy Reporter Yoo Hyun-seok] NaturalFNP, a subsidiary of NextBT, a health functional food specialist company, announced on the 25th that it has signed a supply contract for beta-glucan (β-glucan) with distribution specialist BetaGen Networks.

Under this contract, NaturalFNP will produce beta-glucan products applying its own patents with an annual scale of at least 5 billion KRW and supply them to BetaGen Networks through its parent company NextBT. BetaGen Networks plans to exclusively sell the products domestically and in China using its distribution network.

Beta-glucan is an immune substance that activates the immune function of normal cells. It is effective in suppressing the proliferation and recurrence of cancer cells through non-specific immune responses and in reducing blood sugar and blood cholesterol levels.

NaturalFNP’s beta-glucan applies patents such as “Composition containing glucan oligomers with coronavirus inhibitory activity” and “Manufacturing method for immune activation or cancer disease prevention and treatment.”

A company official said, “With the spread of new and mutant infectious diseases such as COVID-19, demand for immune-enhancing products is also increasing. We will strengthen market competitiveness and improve performance through active response to demand.” He added, “We will strive to contribute to human health by promptly responding to product demand through more active research and development (R&D).”

This content was produced with the assistance of AI translation services.